Pomalidomide
- Generic Name
- Pomalidomide
- Brand Names
- Imnovid, Pomalyst, Imnovid (previously Pomalidomide Celgene), Pomalidomide Viatris, Pomalidomide Zentiva, Pomalidomide Krka, Pomalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C13H11N3O4
- CAS Number
- 19171-19-8
- Unique Ingredient Identifier
- D2UX06XLB5
- Background
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
- Indication
Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also indicated for the treatment of Kaposi's sarcoma (KS) in AIDS patients who have failed highly active antiretroviral thera...
- Associated Conditions
- Kaposi's Sarcoma, Multiple Myeloma (MM)
- Associated Therapies
- -
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2019-09-30
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 290
- Registration Number
- NCT04108195
- Locations
- 🇨🇦
Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta, Canada
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸City of Hope Orange County Lennar Foundation Cancer Center, Irvine, California, United States
Ixazomib + Pomalidomide + Dexamethasone In MM
- Conditions
- Interventions
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Omar Nadeem, MD
- Target Recruit Count
- 61
- Registration Number
- NCT04094961
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Study to Evaluate CCS1477 in Haematological Malignancies
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- CellCentric Ltd.
- Target Recruit Count
- 250
- Registration Number
- NCT04068597
- Locations
- 🇺🇸
Mayo Clinic, Phoenix, Arizona, United States
🇬🇧The Royal Marsden, Sutton, Surrey, United Kingdom
🇫🇷Institute Gustave Roussy, Villejuif, France
Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
- Conditions
- Interventions
- First Posted Date
- 2019-08-06
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 56
- Registration Number
- NCT04045795
- Locations
- 🇦🇺
Investigational Site Number : 0360004, Fitzroy, Victoria, Australia
🇺🇸~Banner MD Anderson Cancer Center Site Number : 8400005, Gilbert, Arizona, United States
🇯🇵Investigational Site Number : 3920002, Okayama-shi, Okayama, Japan
A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
- Conditions
- Interventions
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Takeda
- Target Recruit Count
- 50
- Registration Number
- NCT03984097
- Locations
- 🇺🇸
American Oncology Partners of Maryland, PA, Bethesda, Maryland, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Pacific Cancer Care, Monterey, California, United States
A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders
- Conditions
- Interventions
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 10
- Registration Number
- NCT03959358
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Academic and Community Cancer Research United
- Registration Number
- NCT03841565
- Locations
- 🇺🇸
Cancer Center of Kansas - Wichita, Wichita, Kansas, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸State University of New York Upstate Medical University, Syracuse, New York, United States
An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments
- Conditions
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 15
- Registration Number
- NCT03828292
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma
- First Posted Date
- 2019-01-09
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 3
- Registration Number
- NCT03798314
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Emory University
- Target Recruit Count
- 29
- Registration Number
- NCT03756896
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.